Agendia has named Jan Groen to the post of chief operating officer. Groen previously was VP of research and development at Focus Diagnostics, and he was co-founder and R&D director at ViroClinics. Groen also was a virologist at the Erasmus Medical Center in Rotterdam, the Netherlands, and had worked at the management level at the National Institute of Public Health and Environmental Protection in the Netherlands.
Decode Genetics has appointed Axel Nielson to be chief operating officer until the company’s next annual meeting of its board of directors, the company stated in an SEC filing this week. Nielson has worked in several positions at Decode, including CFO, VP of finance, treasurer, VP of investor relations, COO of US operations, and VP of operations.
Seattle Genetics announced last week that John McLaughlin and Daniel Welch joined its board of directors, and Eric Dobmeier was promoted to the newly created position of chief business officer.
McLaughlin is currently CEO of Anesiva, and before that he was president of Tularik, a company acquired by Amgen in 2004.
Welch is currently CEO and president of InterMune. Previously, he was the chairman and CEO of Triangle Pharmaceuticals, acquired by Gilead in 2003.
Dobmeier has been with Seattle Genetics for more than five years in various positions; most recently he was senior VP of corporate development.